Fate Therapeutics (FATE) Interest & Investment Income (2013 - 2026)

Fate Therapeutics has reported Interest & Investment Income for 14 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 44.03% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $9.6 million (down 41.83% YoY), and the FY2025 full-year result was $11.1 million, down 36.07% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $1.9 million, down from $2.2 million in the prior quarter.
• The five-year high for Interest & Investment Income was $4.8 million in Q2 2024, with the low at $418000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $3.1 million across 5 years, with a median of $3.3 million in 2025.
• Annual changes were most pronounced in 2022 — Interest & Investment Income jumped 869.7% — and 2026, when it plunged 44.03%.
• Fate Therapeutics' Interest & Investment Income stood at $2.9 million in 2022, then surged by 53.26% to $4.4 million in 2023, then declined by 12.23% to $3.9 million in 2024, then slumped by 42.69% to $2.2 million in 2025, then retreated by 15.9% to $1.9 million in 2026.
• The last three Interest & Investment Income figures came in at $1.9 million (Q1 2026), $2.2 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.